Clinical Trial Detail

NCT ID NCT01517243
Title Phase II Study of Alternating Sunitinib and Temsirolimus
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dartmouth-Hitchcock Medical Center
Indications

renal cell carcinoma

Therapies

Temsirolimus

Sunitinib

Age Groups: senior adult

No variant requirements are available.